KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amneal Pharmaceuticals (AMRX) Net Income (2017 - 2025)

Amneal Pharmaceuticals has reported Net Income over the past 9 years, most recently at $49.6 million for Q4 2025.

  • Quarterly results put Net Income at $49.6 million for Q4 2025, up 339.0% from a year ago — trailing twelve months through Dec 2025 was $127.9 million (up 273.17% YoY), and the annual figure for FY2025 was $127.9 million, up 273.17%.
  • Net Income for Q4 2025 was $49.6 million at Amneal Pharmaceuticals, up from $18.1 million in the prior quarter.
  • Over the last five years, Net Income for AMRX hit a ceiling of $49.6 million in Q4 2025 and a floor of -$240.1 million in Q2 2022.
  • Median Net Income over the past 5 years was $4.7 million (2022), compared with a mean of -$11.5 million.
  • Peak annual rise in Net Income hit 1148.41% in 2023, while the deepest fall reached 1483.18% in 2023.
  • Amneal Pharmaceuticals' Net Income stood at -$20.4 million in 2021, then surged by 71.12% to -$5.9 million in 2022, then plummeted by 1483.18% to -$93.3 million in 2023, then surged by 77.78% to -$20.7 million in 2024, then skyrocketed by 339.0% to $49.6 million in 2025.
  • The last three reported values for Net Income were $49.6 million (Q4 2025), $18.1 million (Q3 2025), and $35.6 million (Q2 2025) per Business Quant data.